Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 9/20 | 0.37 |
| ▸ | MGLL | Q99685 | 5/20 | 0.37 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.35 |
| ▸ | OXTR | P30559 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30553155 | 1.00 | IP6K1 (0.37) | IP6K1MGLLABHD6OXTRSCN9A | |
| SCHEMBL25326402 | 0.83 | DGAT1 (0.35) | MGLLABHD6OXTR | |
| SCHEMBL25323909 | 0.83 | MGLL (0.37) | MGLLABHD6SCN9AACACB | |
| SCHEMBL25326537 | 0.80 | MMP1 (0.39) | IP6K1MGLLOXTR | |
| SCHEMBL30553301 | 0.80 | MMP1 (0.39) | IP6K1MGLLOXTR | |
| SCHEMBL25324404 | 0.78 | MGLL (0.41) | MGLL | |
| SCHEMBL25328508 | 0.78 | LOXL2 (0.36) | MGLLSSTR4ACACB | |
| SCHEMBL30410656 | 0.77 | MGLL (0.51) | IP6K1MGLLABHD6 | |
| SCHEMBL25325688 | 0.76 | MGLL (0.37) | MGLL | |
| SCHEMBL30553299 | 0.76 | MGLL (0.37) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | claimed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | claimed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | IP6K1 3507/4885MGLL 3523/4885ABHD6 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.